Matinas BioPharma Holdings, Inc. Stock price

Equities

MTNB

US5768101058

Biotechnology & Medical Research

Market Closed - Nyse 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.271 USD -6.52% Intraday chart for Matinas BioPharma Holdings, Inc. +1.80% +25.35%
Sales 2024 * - Sales 2025 * - Capitalization 62.98M
Net income 2024 * -26M Net income 2025 * -29M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-2.52 x
P/E ratio 2025 *
-2.9 x
Employees 34
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.08%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Matinas BioPharma Holdings, Inc., 2023 Earnings Call, Mar 27, 2024
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation CI
North American Morning Briefing : Markets on Hold -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution CI
Matinas Reaches Agreement With FDA For Late-Stage Invasive Aspergillosis Trial MT
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis CI
Sector Update: Health Care Stocks Gain Late Afternoon MT
Matinas BioPharma Shares Rise After Studies Show Successful Oral Delivery of Genetic Material Using its Technology MT
Sector Update: Health Care MT
Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides CI
Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA CI
Transcript : Matinas BioPharma Holdings, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news

Latest transcript on Matinas BioPharma Holdings, Inc.

1 day+1.47%
1 week+0.66%
Current month+3.50%
1 month+8.33%
3 months+19.30%
6 months+120.12%
Current year+34.09%
More quotes
1 week
0.25
Extreme 0.2541
0.43
1 month
0.22
Extreme 0.2226
0.43
Current year
0.18
Extreme 0.1805
0.43
1 year
0.11
Extreme 0.1103
0.89
3 years
0.11
Extreme 0.1103
1.61
5 years
0.11
Extreme 0.1103
2.49
10 years
0.11
Extreme 0.1103
3.99
More quotes
Managers TitleAgeSince
Founder 50 13-04-30
Director of Finance/CFO 55 19-01-02
Chief Tech/Sci/R&D Officer 56 20-11-30
Members of the board TitleAgeSince
Founder 91 13-04-30
Director/Board Member 62 20-09-13
Chairman 55 17-04-02
More insiders
Date Price Change Volume
24-03-28 0.271 -6.52% 1 205 189
24-03-27 0.2899 +1.47% 1,038,009
24-03-26 0.2857 -1.55% 1,186,869
24-03-25 0.2902 +4.39% 3,064,437
24-03-22 0.278 +4.43% 22,244,560

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform) to maximize global clinical impact and patient access. The Company's lead anti-fungal product candidate, MAT2203, is an application of its LNC Platform to a broad spectrum and potent anti-fungal drug called amphotericin B. Its second clinical-stage LNC-based product candidate is MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including NTM, as well as various multidrug-resistant gram-negative and intracellular bacterial infections. It also has internal discovery programs ongoing in the formulation and delivery of small oligonucleotides, namely antisense oligonucleotides (ASOs) and silencing or short interfering RNAs (siRNAs).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2899 USD
Average target price
0.65 USD
Spread / Average Target
+124.22%
Consensus
  1. Stock
  2. Equities
  3. Stock Matinas BioPharma Holdings, Inc. - Nyse